| Literature DB >> 34008425 |
Matthew D Galsky1, Christopher J Hoimes2, Andrea Necchi3, Neal Shore4, J Alfred Witjes5, Gary Steinberg6, Jens Bedke7, Hiroyuki Nishiyama8, Xiao Fang9, Ritesh Kataria9, Eric Sbar9, Xieyang Jia9, Arlene Siefker-Radtke10.
Abstract
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. Neoadjuvant chemotherapy before radical cystectomy (RC) improves outcomes in cisplatin-eligible patients; however, the improvement in overall survival is modest. Standard of care for cisplatin-ineligible patients remains RC; more effective systemic therapies are needed. Recent Phase Ib/II studies suggest pembrolizumab monotherapy and combination therapy are effective neoadjuvant therapies for MIBC. The randomized Phase III KEYNOTE-866 and KEYNOTE-905/EV-303 studies are being conducted to evaluate efficacy and safety of perioperative pembrolizumab or placebo with chemotherapy in cisplatin-eligible patients with MIBC (KEYNOTE-866) and of pembrolizumab monotherapy versus pembrolizumab plus enfortumab vedotin versus RC plus pelvic lymph node dissection alone in cisplatin-ineligible patients with MIBC (KEYNOTE-905/EV-303). Clinical trial registration: NCT03924856 & NCT03924895 (ClinicalTrials.gov).Entities:
Keywords: antibody–drug conjugate; immunotherapy; muscle-invasive bladder cancer; nectin-4; pembrolizumab; perioperative; programmed death 1; radical cystectomy
Mesh：
Substances：
Year: 2021 PMID： 34008425 DOI： 10.2217/fon-2021-0273
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404